Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis

Inflammatory Bowel Diseases

Volumn 10, Issue 3, 2004, Pages 258-260

  Daniel, Fady ^a   Seksik, Philippe ^a   Cacheux, Wulfran ^a   Jian, Raymond ^a   Marteau, Philippe ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

4 ASA; 5 ASA; Inflammatory bowel disease; Pancreatitis; Treatment

Indexed keywords

AMINOSALICYLIC ACID; AMYLASE; AZATHIOPRINE; BETAMETHASONE; BUDESONIDE; CORTICOSTEROID DERIVATIVE; ENEMA; MESALAZINE; PREDNISONE; QUADRASA; TRIACYLGLYCEROL LIPASE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACNE; ACUTE PANCREATITIS; ADULT; AMYLASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DRUG CROSS REACTIVITY; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; ECHOGRAPHY; ENTERITIS; FEMALE; FEVER; HEADACHE; HEART DISEASE; HEMATOLOGIC DISEASE; HIRSUTISM; HISTOLOGY; HUMAN; INCREASED APPETITE; IRRITABILITY; KIDNEY DISEASE; LIVER DYSFUNCTION; LUNG DISEASE; MALE; MOON FACE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; ULCERATIVE COLITIS; VOMITING; WEIGHT GAIN;

ADULT; DRUG TOLERANCE; ENEMA; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; P-AMINOSALICYLIC ACID; PANCREATITIS, ACUTE NECROTIZING; TREATMENT OUTCOME;

EID: 2442426495     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200405000-00013     Document Type: Article

References (20)

1. Gisbert JP, Gomollon F, Mate J, et al. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci. 2002;47:471-488.
2. Marteau P, Nelet F, Le Lu M. et al. Adverse events in patients treated with aminosalicylic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther. 1996;10:949-956.
3. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51:536-539.
4. Decocq G, Gras-Champel V, Vrolant-Mille C, et al. Acute pancreatitis induced by drugs derived from 5-aminosalicylic acid: case report and review of the literature. Therapie. 1999;54:41-48.
5. Campieri M, Lanfranchi GA, Bertoni F. et al. A double-blind trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion. 1984;29:204-208.
6. Selby WS, Bennett MK, Jewell DP. Topical treatment of distal ulcerative colitis with 4-aminosalicylic acid enemas. Digestion. 1984;29:231-234.
7. Gandolfo J, Farthing M, Powers G, et al. 4-aminosalicylic acid retention enemas in treatment of distal colitis. Dig Dis Sci. 1987;32:700-704.
8. Sharma MP, Duphare HV, Dasarathy S. A prospective randomized double blind trial comparing prednisolone and 4-aminosalicylic acid enemas in acute distal ulcerative colitis. J Gastroenterol Hepatol. 1992;7:173-177.
9. Ginsberg AL, Beck LS, Mc Intosh TM, et al. Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double blind, placebo controlled trial. Ann Int Med. 1988;108:195-199.
10. O'Donnel LJ, Arvind AS, Hoang P. et al. Double blind controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis. Gut. 1992;33:947-949.
11. Marteau P, Halphen M. Comparative randomized open study of the efficacy and tolerance of enemas with 2 gr of 4-amino-salicylic acid (4-ASA) and 1 gr of 5-amino-salicylic acid (5-ASA) in distal forms of hemorrhagic rectocolitis. Gastroenterol Clin Biol. 1995;119:31-35 (in French).
12. Beeken W, Howard D, Bigelow J. et al. Controlled trial of 4-ASA in ulcerative colitis. Dig Dis Sci. 1997;42:354-358.
13. Ginsberg AL, Davis ND, Nochomovitz LE. Placebo-controlled trial of ulcerative colitis treatment with oral 4-aminosalicylic acid. Gastroenterology. 1992;102:448-452.
14. Schreiber S, Howaldt S, Raedler A. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind controlled pilot study in the maintenance treatment of Crohn's ileocolitis. Gut. 1994;35: 1081-1085.
15. Begaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie. 1985;40:111-118.
16. Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am. 1993;77:1253-1262.
17. Simpson DG, Walker JH. Hypersensitivity to para-aminosalicylic acid. Am J Med. 1960;29:297-306.
18. Norgine Pharma. Quadrasa® enema periodic safety update report, 01/04/1998 to 31/12/2000 and 01/01/2001 to 30/04/2002 internal files.
19. Jacobsen BA, Abildgaard K, Rasmussen HH, et al. Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions. Scand J Gastroenterol. 1991;26:374-378.
20. Hauben R. Human pharmacokinetics and bioavailability of a 2g 4ASA enema, QUADRASA® AMM file, part IV.